453 related articles for article (PubMed ID: 23268333)
1. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
2. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
3. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
5. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
6. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
7. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
Nozato M; Kaneko S; Nakagawara A; Komuro H
Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
10. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
11. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
13. High genomic instability predicts survival in metastatic high-risk neuroblastoma.
Stigliani S; Coco S; Moretti S; Oberthuer A; Fischer M; Theissen J; Gallo F; Garavent A; Berthold F; Bonassi S; Tonini GP; Scaruffi P
Neoplasia; 2012 Sep; 14(9):823-32. PubMed ID: 23019414
[TBL] [Abstract][Full Text] [Related]
14. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
16. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
[TBL] [Abstract][Full Text] [Related]
17. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
[TBL] [Abstract][Full Text] [Related]
18. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
19. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG
J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
